The study of ischemia modified albumin as an early biomarker of epilepsy in adolescent population: a cross-sectional study.
adolescent
albumin
epilepsy
hypoxia
ischemia
oxidative stress
Journal
Hormone molecular biology and clinical investigation
ISSN: 1868-1891
Titre abrégé: Horm Mol Biol Clin Investig
Pays: Germany
ID NLM: 101538885
Informations de publication
Date de publication:
04 Feb 2021
04 Feb 2021
Historique:
received:
03
09
2020
accepted:
17
01
2021
pubmed:
6
2
2021
medline:
29
12
2021
entrez:
5
2
2021
Statut:
epublish
Résumé
Epilepsy is one of the most common neurological disorders, diagnosis of which is challenging as many unrelated conditions may mimic seizure. Epilepsy impairs the quality of life of patients due to associated physical and psychological trauma. Epileptic patients are also at increased risk of premature death due to autonomic disturbance and fatal accidents. The aim of the present research work was to study ischemia modified albumin (IMA) as an early biomarker of epilepsy in the adolescent population. Twenty-five diagnosed cases of epilepsy and 25 healthy volunteers as control of adolescent group were recruited as study subjects. The study subjects were age and sex matched. Clinical evaluation, routine biochemical parameters and IMA estimation were carried out. Serum IMA was measured by spectrophotometric method. The mean serum IMA levels were significantly raised in epileptic patients (0.69 IMA may be used as a biomarker for early diagnosis of epilepsy as well as to differentiate epileptic seizure from various non epileptic disorders in the adolescent population.
Identifiants
pubmed: 33544499
pii: hmbci-2020-0060
doi: 10.1515/hmbci-2020-0060
doi:
Substances chimiques
Biomarkers
0
ischemia-modified albumin
0
Serum Albumin, Human
ZIF514RVZR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
183-187Informations de copyright
© 2021 Walter de Gruyter GmbH, Berlin/Boston.
Références
Stafstrom, CE, Carmant, L. Seizures and epilepsy: an overview for neuroscientists. Cold Spring Harbor Perspect Med 2015:5:022426. https://doi.org/10.1101/cshperspect.a022426.
Meyer, AC, Dua, T, Ma, J, Saxena, S, Birbeck, G. Global disparities in the epilepsy treatment gap: a systematic review. Bull World Health Organ 2010;88:260–6. https://doi.org/10.2471/blt.09.064147.
Amudhan, S, Gururaj, G, Satishchandra, P. Epilepsy in India I: epidemiology and public health. Ann Indian Acad Neurol 2015;18:263. https://doi.org/10.4103/0972-2327.160093.
Santhosh, NS, Sinha, S, Satishchandra, P. Epilepsy: Indian perspective. Ann Indian Acad Neurol 2014;17(Suppl 1):S3. https://doi.org/10.4103/0972-2327.128643.
Shin, HW, Jewells, V, Hadar, E, Fisher, T, Hinn, A. Review of epilepsy-etiology, diagnostic evaluation and treatment. Int J Neurorehabilitation 2014;1:2376–0281.
Bhalla, D, Godet, B, Druet-Cabanac, M, Preux, PM. Etiologies of epilepsy: a comprehensive review. Exp Rev Neurother 2011;11:861–76. https://doi.org/10.1586/ern.11.51.
Yin, YH, Ahmad, N, Makmor-Bakry, M. Pathogenesis of epilepsy: challenges in animal models. Iran J Basic Med Sci 2013;16:1119.
Gaze, DC. Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia. Drug Metab Pharmacokinet 2009;24:333–41. https://doi.org/10.2133/dmpk.24.333.
Onis, MD, Onyango, AW, Borghi, E, Siyam, A, Nishida, C, Siekmann, J. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ 2007;85:660–7. https://doi.org/10.2471/blt.07.043497.
Kamasak, T, Turedi, S, Serin, HM, Mentese, A, Gündüz, A, Alver, A, et al.. Can ischemia-modified albumin be used to differentiate between generalized seizures and pseudoseizures? Turk J Med Sci 2017;47:282–6.
Bar–Or, D, Lau, E, Winkler, JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia—a preliminary report. J Emerg Med 2000;19:311–5.
Uzel, M, Oray, NC, Bayram, B, Kume, T, Girgin, MC, Doylan, O, et al.. Novel biochemical marker for differential diagnosis of seizure: ischemia-modified albumin. Am J Emerg Med 2014;32:962–5. https://doi.org/10.1016/j.ajem.2014.05.003.
Kobylarek, D, Iwanowski, P, Lewandowska, Z, Limphaibool, N, Szafranek, S, Labrzycka, A, et al.. Advances in the potential biomarkers of epilepsy. Front Neurol 2019:10.
Ristić, AJ, Savić, D, Sokić, D, Bogdanović Pristov, J, Nestorov, J, Baščarević, V, et al.. Hippocampal antioxidative system in mesial temporal lobe epilepsy. Epilepsia 2015;56:789–99.
Gaze, DC. Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia. Drug Metabol Pharmacokine 2009;24:333–41. https://doi.org/10.2133/dmpk.24.333.
Bar–Or, D, Lau, E, Winkler, JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia—a preliminary report 1. J Emerg Med 2000;19:311–5.
Abboud, H, Labreuche, J, Meseguer, E, Lavallee, PC, Simon, O, Olivot, JM, et al.. Ischemia-modified albumin in acute stroke. Cerebrovasc Dis 2007;23:216–20. https://doi.org/10.1159/000097644.
Kocaoglu, C, Caksen, H, Atabek, ME, Kurku, H, Arslan, S. Serum ischemia-modified albumin levels in children with epileptic seizures. Pediatr Emerg Care 2014.
Inci, A, Gencpinar, P, Orhan, D, Uzun, G, Ozdem, S, Samur, AA, et al.. Ischemia-modified albumin levels in children having seizure. Brain and Development 2013;35:849. https://doi.org/10.1016/j.braindev.2012.11.004.